Literature DB >> 24931317

Missing data sensitivity analysis for recurrent event data using controlled imputation.

Oliver N Keene1, James H Roger, Benjamin F Hartley, Michael G Kenward.   

Abstract

Statistical analyses of recurrent event data have typically been based on the missing at random assumption. One implication of this is that, if data are collected only when patients are on their randomized treatment, the resulting de jure estimator of treatment effect corresponds to the situation in which the patients adhere to this regime throughout the study. For confirmatory analysis of clinical trials, sensitivity analyses are required to investigate alternative de facto estimands that depart from this assumption. Recent publications have described the use of multiple imputation methods based on pattern mixture models for continuous outcomes, where imputation for the missing data for one treatment arm (e.g. the active arm) is based on the statistical behaviour of outcomes in another arm (e.g. the placebo arm). This has been referred to as controlled imputation or reference-based imputation. In this paper, we use the negative multinomial distribution to apply this approach to analyses of recurrent events and other similar outcomes. The methods are illustrated by a trial in severe asthma where the primary endpoint was rate of exacerbations and the primary analysis was based on the negative binomial model.
Copyright © 2014 John Wiley & Sons, Ltd.

Entities:  

Keywords:  MNAR; exacerbation; missing; multiple imputation; recurrent event; sensitivity

Mesh:

Year:  2014        PMID: 24931317     DOI: 10.1002/pst.1624

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  9 in total

1.  Effect of Aclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease: The ASCENT-COPD Randomized Clinical Trial.

Authors:  Robert A Wise; Kenneth R Chapman; Benjamin M Scirica; Deepak L Bhatt; Sami Z Daoud; Sofia Zetterstrand; Colin Reisner; Esther Garcia Gil
Journal:  JAMA       Date:  2019-05-07       Impact factor: 56.272

2.  Efficient Multiple Imputation for Sensitivity Analysis of Recurrent Events Data with Informative Censoring.

Authors:  Guoqing Diao; Guanghan F Liu; Donglin Zeng; Yilong Zhang; Gregory Golm; Joseph F Heyse; Joseph G Ibrahim
Journal:  Stat Biopharm Res       Date:  2020-11-05       Impact factor: 1.586

3.  Improving the evaluation of COPD exacerbation treatment effects by accounting for early treatment discontinuations: a post-hoc analysis of randomized clinical trials.

Authors:  Agnieszka Król; Robert Palmér; Virginie Rondeau; Stephen Rennard; Ulf G Eriksson; Alexandra Jauhiainen
Journal:  Respir Res       Date:  2020-06-22

4.  Reference-based sensitivity analysis for time-to-event data.

Authors:  Andrew Atkinson; Michael G Kenward; Tim Clayton; James R Carpenter
Journal:  Pharm Stat       Date:  2019-07-15       Impact factor: 1.894

5.  Reference-based multiple imputation for missing data sensitivity analyses in trial-based cost-effectiveness analysis.

Authors:  Baptiste Leurent; Manuel Gomes; Suzie Cro; Nicola Wiles; James R Carpenter
Journal:  Health Econ       Date:  2019-12-17       Impact factor: 3.046

6.  Missing not at random in end of life care studies: multiple imputation and sensitivity analysis on data from the ACTION study.

Authors:  Giulia Carreras; Guido Miccinesi; Andrew Wilcock; Nancy Preston; Daan Nieboer; Luc Deliens; Mogensm Groenvold; Urska Lunder; Agnes van der Heide; Michela Baccini
Journal:  BMC Med Res Methodol       Date:  2021-01-09       Impact factor: 4.615

Review 7.  A review of the use of controlled multiple imputation in randomised controlled trials with missing outcome data.

Authors:  Ping-Tee Tan; Suzie Cro; Eleanor Van Vogt; Matyas Szigeti; Victoria R Cornelius
Journal:  BMC Med Res Methodol       Date:  2021-04-15       Impact factor: 4.615

8.  Efficacy and safety of fevipiprant in patients with uncontrolled asthma: Two replicate, phase 3, randomised, double-blind, placebo-controlled trials (ZEAL-1 and ZEAL-2).

Authors:  Mario Castro; Edward Kerwin; David Miller; Andrew Pedinoff; Lawrence Sher; Pamela Cardenas; Barbara Knorr; David Lawrence; Diego Ossa; Wei Wang; Jorge F Maspero
Journal:  EClinicalMedicine       Date:  2021-04-25

9.  A four-step strategy for handling missing outcome data in randomised trials affected by a pandemic.

Authors:  Suzie Cro; Tim P Morris; Brennan C Kahan; Victoria R Cornelius; James R Carpenter
Journal:  BMC Med Res Methodol       Date:  2020-08-12       Impact factor: 4.615

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.